Purpose / DescriptionThis phase 3 randomized, double-blind placebo-controlled trial evaluated the safety and efficacy of 12 weeks of therapy with glecaprevir-pibrentasvir in patients with genotype 2 hepatitis C infection without cirrhosis. Thirty percent were treatment-experienced; most (91%) had received interferon-based while the remainder sofosbuvir-based therapy. Among DAA-naive patients who received glecaprevir-pibrentasvir, 195 (99%) of 196 achieved a sustained virologic response 12 (SVR12) by intent-to-treat analysis. There were no serious adverse events related to glecaprevir-pibrentasvir. Findings from ENDURANCE-2 were published in conjunction with ENDURANCE-4 and SURVEYOR-II, Part 4.